Business Wire

HUMAN-FRATERNITY-MEETING

8.5.2020 17:44:11 CEST | Business Wire | Press release

Share
Higher Committee of Human Fraternity Calls for Global Day of Prayer on May 14 in Response to COVID-19

The Higher Committee of Human Fraternity (HCHF), called on religious leaders and faithful around the world to a day of fasting, prayers and supplications for the good of all humanity on Thursday, May 14 for an end to the novel coronavirus (COVID-19) pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200508005369/en/

The call is part of the Committee’s (HCHF) efforts to realize the objectives of the Document on Human Fraternity. It invites people around the world to lay all their differences aside and come together and assume their responsibilities against this virus, the first and true enemy of humanity in this era.

Judge Mohamed Abdel Salam , Secretary-General of the Committee (HCHF) said: “The overwhelming response with this call for prayer from leaders and peoples around the world is a true testament to human solidarity and grants us hope in achieving global unity based on human fraternity principles for the safety, security and health of all mankind.”

He also noted that seeing all believers come together in prayers and supplications for an end to this pandemic is dream come true of a universal human unity, which is much needed now more than ever. “We will implore God Almighty for his grace and mercy and trust that He will respond to the hopes of millions of faithful asking to be saved from this deadly pandemic,” he continued.

US-based Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation and member of the Committee (HCHF) added: “Just as all of us have seen how the global pandemic has taken lives and livelihoods, we have also witnessed it reveal some of the best qualities in humankind.”

Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis and member of the Committee (HCHF), said: “As we await a cure that would spare humanity from this deadly pandemic, our only hope is that God Almighty will save the millions suffering around the world, and help scientists and researchers to succeed in finding the eagerly-awaited cure.”

The Committee (HCHF) seeks to bring humanity together in prayer on Thursday, May 14, in what will be the largest gathering of humanity for one goal. The event will be accompanied by unprecedented media coverage, through the Committee’s social media accounts with hashtag #PrayForHumanity to allow people to interact and share their videos, photos and posts.

The Committee (HCHF) is an independent body of religious leaders, educational scholars and cultural figures from across the world, dedicated to achieving the noble goals of the Document on Human Fraternity signed by Pope Francis and Sheikh Ahmed el-Tayeb, Grand Imam of Al-Azhar, during the Pope’s Apostolic Journey to the United Arab Emirates in February 2019, under the patronage of H.H Sheikh Mohammed Bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye